妊娠与哺乳期相关骨质疏松症治疗干预的比较效果:系统评价与Meta分析
该系统评价与Meta分析检索至2022年12月20日的PubMed/Scopus数据库,纳入66项研究(n=451)定性分析,仅2项干预性研究进行Meta分析。特立帕肽较钙/维生素D更能增加腰椎和股骨颈骨密度,但异质性高且缺乏稳健比较数据,无法就最佳治疗得出安全结论。
要点
- 纳入66项研究(n=451),随访6-264个月,年龄19-42岁。
- 特立帕肽较钙/维生素D增加腰椎骨密度(WMD 11.5%,95%CI 4.9-18.0%,I²=50.9%)。
- 因异质性高且缺乏稳健比较数据,无法就最佳干预得出安全结论。
核心结论
- 由于异质性高且缺乏稳健的比较数据,无法就妊娠与哺乳期相关骨质疏松症女性的最佳治疗干预得出安全结论。
研究设计与样本
- 系统评价与Meta分析,检索PubMed/Scopus数据库截至2022年12月20日,纳入66项研究(n=451)进行定性分析,仅2项干预性研究进行Meta分析。
主要发现
- 钙/维生素D、双膦酸盐和特立帕肽在12个月时腰椎骨密度增幅分别为2.0%至7.5%、5.0%至41.5%和8.0%至24.4%,24个月时分别为11.0%至12.2%、10.2%至171.9%和24.1%至32.9%。
- 股骨颈骨密度在18-24个月时钙/维生素D增加6.1%,双膦酸盐增加0.7%至18%,特立帕肽增加8.4%至18.6%。
- Meta分析显示特立帕肽较钙/维生素D增加腰椎骨密度(WMD 11.5%,95%CI 4.9-18.0%,I²=50.9%)和股骨颈骨密度(WMD 5.4%,95%CI 1.2-9.6%,I²=8.1%)。
局限性
- 由于异质性高且缺乏稳健的比较数据,无法就最佳治疗干预得出安全结论。
- 仅2项干预性研究进行了Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The optimal management of pregnancy and lactation-associated osteoporosis (PLO) has not been designated. OBJECTIVE: To systematically review the best available evidence regarding the effect of different therapeutic interventions on bone mineral density (BMD) and risk of fractures in these patients. METHODS: A comprehensive search was conducted in PubMed/Scopus databases until December 20, 2022. Data were expressed as weighted mean difference (WMD) with 95% CI. The I2 index was employed for heterogeneity. Studies conducted in women with PLO who received any antiosteoporosis therapy were included. Studies including women with secondary causes of osteoporosis or with transient osteoporosis of the hip were excluded. Data extraction was independently completed by 2 researchers. RESULTS: Sixty-six studies were included in the qualitative analysis (n = 451 [follow-up time range 6-264 months; age range 19-42 years]). The increase in lumbar spine (LS) BMD with calcium/vitamin D (CaD), bisphosphonates, and teriparatide was 2.0% to 7.5%, 5.0% to 41.5%, and 8.0% to 24.4% at 12 months, and 11.0% to 12.2%, 10.2% to 171.9%, and 24.1% to 32.9% at 24 months, respectively. Femoral neck (FN) BMD increased by 6.1% with CaD, and by 0.7% to 18% and 8.4% to 18.6% with bisphosphonates and teriparatide (18-24 months), respectively. Meta-analysis was performed for 2 interventional studies only. Teriparatide induced a greater increase in LS and FN BMD than CaD (WMD 11.5%, 95% CI 4.9-18.0%, I2 50.9%, and 5.4%, 95% CI 1.2-9.6%, I2 8.1%, respectively). CONCLUSION: Due to high heterogeneity and lack of robust comparative data, no safe conclusions can be made regarding the optimal therapeutic intervention in women with PLO.
引用
- Anagnostis P, Lampropoulou-Adamidou K, Bosdou JK, et al. Comparative Effectiveness of Therapeutic Interventions in Pregnancy and Lactation-Associated Osteoporosis: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2024. PMID: 37708365. doi:10.1210/clinem/dgad548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。